Wobble Genomics has appointed two new non-executive directors to its board as part of its plans to grow and expand the company.
The life sciences company, which specialises in RiboNucleic Acid (RNA), appointed Trevor Nicholls and John Leamon to the board.
Trevor Nicholls brings 40 years’ experience of building international businesses in the life sciences industry, with a focus on genomics, pharma, and biotech.
He worked at McKinsey & Company at the beginning of his career before moving on to a number of senior roles within the life science industry.
He worked as a commercial director of the life science business at Amersham International (now Cytiva), chief executive at University of Oxford genomics technology spin-out Oxagen, and chief commercial officer of Affymetrix.
He was the chair of Oxford Nanopore Technologies in its early years, with the company raising more than £100m from private and institutional investors during his tenure.
US-based John Leamon’s experience is as a scientist and executive with a background in nucleic acid amplification, next generation DNA sequencing, microfluidics, genetics, molecular biology, and product development.
He has held positions at 454 Life Sciences, Ion Torrent, Qiagen, and Quantum-Si. Most recently, Leamon has been a SVP of research and development integration at IsoPlexis, advisory board member at Cofactor Genomics, head of strategic partnerships at Homodeus, and head of product development at 4Catalyzer.
Richard Kuo, chief executive and founder at Wobble Genomics, said: “Trevor and John are two of the most highly respected individuals in the industry, who bring years of experience and know-how – in terms of running life sciences and biotech businesses, scaling them, product development, global sales, and raising investment from venture capitalists, all things that will be integral to Wobble’s trajectory over the next few months and years.”
Earlier this month, Wobble secured a £1.2m investment round led by St Andrews-based investment firm Eos Advisory, alongside the University of Edinburgh’s in-house venture investment fund Old College Capital.
Don’t miss the latest headlines with our twice-daily newsletter – sign up here for free .